Skip to main content
SpringerLink
Log in

Use of PEG-asparaginase in the treatment of patients with solid tumors

  • Letter to the Editors
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A (1970) Clinical results of treatment with E. coli l-asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer 25:279

    Article  CAS  PubMed  Google Scholar 

  2. Holle LM (1997) Pegaspargase: an alternative? Ann Pharmacother 31:616

    CAS  PubMed  Google Scholar 

  3. Kurtzberg J (1994) A new look at PEG-I,-asparaginase and other asparaginases in hematological malignancies. Cancer Invest 12[Suppl 1]:59

    Google Scholar 

  4. Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, Vieira Pinheiro JP, Winkelhorst M, Boos J (2000) Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 110:379

    Article  PubMed  Google Scholar 

  5. Riccardi R, Holcenberg JS, Glaubinger DL, Wood JH, Poplack DG (1981) I,-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554

    CAS  PubMed  Google Scholar 

  6. Tallal L, Tan C, Oettgen H, Wollner N, McCarthy M, Helson L, Burchenal J, Karnofsky D, Murphy L (1970) E. coli l-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 25:306

    Article  CAS  PubMed  Google Scholar 

  7. Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE (2001) A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated I,-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol 47:83

    Article  CAS  PubMed  Google Scholar 

  8. Wagner A, Schulze-Westhoff P, Jürgens H, Boos J (1998) In vitro monitoring of asparaginase: unphysiological alteration of culture medium. In: Hiddemann W, Büchner T, Wormann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds) Experimental approaches and novel therapies, vol 7. Acute leukemias. Springer, Berlin, p 570

    Google Scholar 

  9. Wagner A, Hempel G, Gumbinger HG, Jürgens H, Boos J (1999) Pharmacokinetics of anticancer drugs in vitro}. Adv Exp Med Biol 457:397

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Oncology, University of Münster, Albert- Schweitzer Str. 33, 48149, Münster, Germany

    João Paulo Vieira Pinheiro, Claudia Lanvers & Joachim Boos

Authors
  1. João Paulo Vieira Pinheiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Lanvers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joachim Boos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Boos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinheiro, J.P.V., Lanvers, C. & Boos, J. Use of PEG-asparaginase in the treatment of patients with solid tumors. Cancer Chemother Pharmacol 48, 421–422 (2001). https://doi.org/10.1007/s002800100361

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800100361

Search

Navigation